StemSynergy Therapeutics, Inc.
"Innovative Stem Cell Research. Targeted Cancer Therapeutics."

Publications

  1. Li, B. et al. Differential abundance of CK1α provides selectivity for pharmacological CK1α activators to target WNT-dependent tumors. Science Signaling 10, eaak9916 (2017).
  2. Li, B. et al. Pyrvinium attenuates Hedgehog signaling downstream of Smoothened. Cancer Research (2014).
  3. Li, B. et al. Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis. PLoS One 9, 1-9 (2014).
  4. Barham, W. et al. Targeting the Wnt pathway in synovial sarcoma models. Cancer Discovery 3, 1286-1301 (2013).
  5. Xu, W. et al. The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer. PLoS One 8, 1-12 (2013).
  6. Thorne, C.A. et al. A biochemical screen for identification of small-molecule regulators of the Wnt pathway using Xenopus egg extracts. Journal of Biomolecular Screening 16, 995-1006 (2011).
  7. Thorne, C.A. et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1 alpha. Nature Chemical Biology 6, 829-836 (2010).

Scientific Team

SSTI has a multidisciplinary team of scientists.

Meet the Team

Leadership

Meet the Leadership behind StemSynergy Therapeutics, Inc.

Meet Leadership

Cancer Research

Targeting the developmental pathways that drive cancer.

Cancer Research